Work

Platelet-to-lymphocyte ratio and overall survival according to first-line immunotherapy exposure in metastatic melanoma: a multicentre retrospective cohort study

Year: 2026
Type: article
Abstract: Purpose We evaluated whether associations between inflammatory and nutritional biomarkers and overall survival (OS) differed according to first-line immunotherapy (IO) exposure in metastatic melanoma. Methods This multicentre retrospective cohort included 236 patients treated during 2010–2025. Seven biomarkers, platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio, C-reactive protein, albumin, lactate dehydrogenase (LDH), and body mass index, were evaluated using Cox regression. Interaction models were adjusted for Eastern Cooperative Oncology Group performance status and LDH (performance status alone for LDH), with Bonferroni correction for seven tests ( p < 0.0071). Extended sensitivity analyses were exploratory. Results Among 236 patients, 81 (34.3%) received first-line IO, and 142 deaths occurred. Elevated PLR was associated with shorter OS in the IO (HR, 6.03; 95% CI, 2.44–14.95) and non-IO (HR, 1.54; 95% CI 1.05–2.24) groups. The adjusted PLR-by-treatment interaction was significant (HR ratio, 4.41; 95% CI, 1.71–11.36; p = 0.002) and remained significant after adjustment for calendar period and BRAF status. In the 2022–2025 subgroup, the interaction was not statistically significant ( p = 0.055). An exploratory second-line analysis using reassessed PLR ( n = 114) yielded an unadjusted interaction HR ratio of 2.95 (95% CI 1.22–7.13; p = 0.016). SII showed no significant interaction (HR ratio, 2.08; p = 0.108), nor did the remaining biomarkers. Conclusions PLR showed treatment-dependent prognostic heterogeneity, but these observational findings do not establish predictive utility for treatment selection. External validation is required.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7237336102
FWCI:
Cites:
Cited by:
Related to: